Jay Campbell joined the Cancer Research Institute (CRI) as Managing Director of the CRI Clinical Accelerator and Venture Fund in October 2020. In this capacity, he is responsible for developing new and managing existing relationships with strategic industry partners, leading the negotiations and contracting of transactions, performing due diligence on new investment opportunities for the venture fund, and managing the existing investment portfolio.
Prior to joining CRI, Jay was the Chief Business Officer of Immutep, a publicly listed immuno-oncology company, and before that he was responsible for business development and investor relations at Kolltan Pharmaceuticals. He spent over 15 years in the financial services industry, 13 of which focused on the life sciences industry as an investment banker working with private and public companies. During this time, he worked on 30 M&A and financing transactions representing more than $13.4 billion
Jay previously served as an advisor to Athena Bioventures, a family office focused on life sciences investments. He served of the board of directors of Update Pharma, Inc., private oncology company. He spent 15 years as a volunteer with Minds Matter of NYC, Inc., a New York City-based not-for-profit organization focused on transforming the lives of accomplished high school students from low-income families by broadening their dreams and preparing them for college success, in various capacities including chairman of the board of directors.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.